CLINICAL_TRIALS
trial_result
· 2016-11-02
Clinical Trial Update: A Study of RO4917838 (Bitopertin) in Patients With Sub-optimally Controlled Symptoms of Schizophrenia (WN25305) [Phase 3]
Summary
This update describes a Phase 3 study of bitopertin (RO4917838) for sub-optimally controlled schizophrenia symptoms. The trial status is completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Hoffmann-La Roche | Conditions: Schizophrenia | Phase 3 | Status: COMPLETED